Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on September 27, 2021, covering events occurring in late September 2021. The filing details the results of a reconvened Special General Meeting of Shareholders, amendments to pending merger and share transfer agreements, and a regulatory notice regarding Nasdaq listing compliance.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it references financial results for the six-month period ended June 30, 2021, which resulted in the Company failing to meet the Nasdaq Listing Rule requirement for a minimum stockholders' equity of $2,500,000. The filing also notes that as of September 20, 2021, the Company did not meet alternative listing requirements based on market value of listed securities or net income from continuing operations.
Material Changes and Corporate Actions
- Shareholder Approval: On September 26, 2021, shareholders passed all agenda items at a reconvened Special General Meeting originally scheduled for September 19, 2021.
- Merger Agreement Amendment: The Outside Date for the merger between Cellect Biotechnology Ltd. (via Merger Sub) and Quoin Pharmaceuticals, Inc. was extended from September 30, 2021, to November 1, 2021.
- Share Transfer Agreement Amendment: The closing deadline for the sale of Cellect Biotherapeutics, Ltd. to EnCellX, Inc. was extended from September 30, 2021, to November 1, 2021.
- Nasdaq Non-Compliance: The Company received a notice of non-compliance from Nasdaq regarding Rule 5550(b)(1) due to insufficient stockholders' equity and failure to meet alternative listing standards.
Outlook, Risks, and Management Commentary
Management intends to submit a plan to regain compliance with Nasdaq listing requirements by November 5, 2021. The primary risk identified is the potential delisting if the Company fails to regain compliance or consummate the pending transactions by the new deadlines. The filing does not provide specific forward-looking financial guidance or commentary on operational performance beyond the transaction updates.
Investor Verification Checklist
- Verify the status of the Nasdaq compliance plan submission by November 5, 2021.
- Confirm the consummation of the merger with Quoin Pharmaceuticals and the share transfer to EnCellX by the new November 1, 2021 deadline.
- Review the Company's most recent audited financial statements to assess the specific stockholders' equity deficit cited by Nasdaq.
- Monitor for any further amendments to the Merger or Share Transfer agreements if the November 1, 2021 deadlines are not met.